NICE recommends routine funding for Novartis’ Kisqali
Drug recommended as a second-line treatment for certain advanced breast cancers
Read Moreby Lucy Parsons | Feb 26, 2021 | News | 0
Drug recommended as a second-line treatment for certain advanced breast cancers
Read Moreby Selina McKee | May 27, 2020 | News | 0
In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trials
Read Moreby Anna Smith | Aug 1, 2019 | News | 0
The success marks the second Phase III clinical trial in which Kisqali met overall survival.
Read Moreby Anna Smith | Jul 17, 2019 | News | 0
NICE has recommended Novartis’ Kisqali just three months after its initial rejection.
Read Moreby Anna Smith | Jun 3, 2019 | News | 0
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer.
Read Moreby Anna Smith | Apr 10, 2019 | News | 0
The drug is typically used with fulvestrant to treat people with advanced breast cancer.
Read Moreby Selina McKee | Jul 19, 2018 | News | 0
Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration.
Read Moreby Selina McKee | Mar 13, 2018 | News | 0
The Scottish Medicines Consortium (SMC has published new guidelines approving NHS funding for medicines for breast cancer and Hodgkin’s lymphoma.
Read Moreby Selina McKee | Jan 3, 2018 | News | 0
Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.
Read Moreby Selina McKee | Dec 7, 2017 | News | 0
Novartis has unveiled Phase III data showing that partnering Kisqali with an endocrine therapy significantly prolonged progression-free survival compared to an endocrine therapy alone in patients with breast cancer.
Read Moreby Selina McKee | Nov 16, 2017 | News | 0
The National Institute for Health and Care Excellence is backing routine NHS funding for Pfizer’s Ibrance and Novartis’ Kisqali to treat certain forms of breast cancer, after the firms agreed to provide them at a reduced price under the new process for appraising medicines.
Read Moreby Selina McKee | Aug 24, 2017 | News | 0
Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
